TITLE:
ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Nave HIV-Infected Subjects

CONDITION:
HIV Infections

INTERVENTION:
Lopinavir/Ritonavir

SUMMARY:

      To assess the safety, tolerability and antiviral activity of lopinavir/ritonavir when
      administered orally in antiretroviral-HIV-1 infected subjects.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria

          -  HIV-1 positive

          -  antiretroviral-adult males

          -  non-pregnant

          -  non-lactating females at least 18-years old with plasma HIV-1 RNA > 5000 copies/mL,
             who were not acutely ill

        Exclusion Criteria

          -  History of:

               -  prior antiretroviral therapy

               -  significant drug hypersensitivity

               -  psychiatric illness that precludes compliance

               -  an active substance abuser

               -  positive test results for drug abuse

               -  abnormal lab test results (hemoglobin, absolute neutrophil count, platelet
                  count, SGPT/AST or SGPT/ALT, creatinine, fasting triglycerides, significant
                  abnormal ECG results

               -  pregnancy or lactating female

               -  received another investigational drug within 28 days of study initiation

               -  unlikely to comply or unsuitable candidate in the opinion of the investigator
      
